Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by INAGAKI, J.
Right arrow Articles by ABE, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by INAGAKI, J.
Right arrow Articles by ABE, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Japanese Journal of Clinical Oncology 9:233-238 (1979)
© 1979 Foundation for Promotion of Cancer Research

research-article

A Comparative Study of DCMP versus DCcMP Combination Chemotherapy for Adult Acute Leukemia

JIRO INAGAKI, M.D.*, NOBORU HORIKOSHI, M.D.*, INOUE KATSUHIRO, M.D.*, TOSHIAKI CHINEN, M.D.*, SYUICHI FUJIMOTO, M.S.*, AKIRA HOSHINO, M.D.*, MAKOTO OGAWA, M.D.*, ISAO NAKAO, M.D.**, YASUNOBU KURAISHI, M.D.***, SADAYASU MEGURO, M.D.***, KENJI ICHIBA, M.D.*** and MASAKAZU ABE, M.D.***

*Department of Clinical Oncology, Cancer Institute Hospital and Division of Clinical Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research Tokyo
**Department of Internal Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research Tokyo
***Third Department of Internal Medicine, Jikei University School of Medicine Tokyo

Received August 6, 1979; An experimental study using L-1210 mouse leukemia indicated that daunomycin, cyclocytidine, and 6-mercaptopurine (DCcM) combination chemotherapy was more effective than daunomycin, cytosine arabinoside, and 6-mercaptopurine (DCM). Based on these results, a clinical study comparing daunomycin, cytosine arabinoside, 6-mercaptopurine, and predni-solone (DCMP) combination chemotherapy with daunomycin, cyclocytidine, 6-mercaptopurine, and prednisolone (DCcMP) in the treatment of adult acute nonlymphocytic leukemia was conducted. Patients were randomly allocated to receive either regimen. Ten of 15 patients treated with DCMP had complete remission for a median duration of 43 weeks and one had partial remission. Seven of 15 patients treated with DCcMP had complete remission for a median duration of 18 weeks and two had partial remission. The patient characteristics before chemotherapy, the toxicity of the chemotherapeutic regimens and the causes for differences in antitumor activity between the experimental study and the clinical study are discussed.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.